Konyagoz Eye Hospital, Sancak Mah. Unluer Sok. No:13, 42000, Selcuklu, Konya, Turkey.
Int Ophthalmol. 2020 Oct;40(10):2487-2494. doi: 10.1007/s10792-020-01427-z. Epub 2020 May 25.
To compare retrospectively two different techniques of Xen implantation, which are transconjunctival (ab-externo) and standard (ab-interno) techniques.
Forty-three eyes of 43 patients with primary open-angle glaucoma (POAG) who had Xen implantation operation via transconjunctival (ab-externo) technique comprised Group 1. Of the 43 patients, 20 (46.5%) were males and 23 (53.5%) were females. Their mean age was 61.76 ± 8.81 (41-74) years. Forty-four eyes of 44 patients with POAG who had Xen implantation operation via standard (ab-interno) technique comprised Group 2. Of the 44 patients, 21 (47.7%) were males and 23 (52.3%) were females. The mean age of this group was 63.80 ± 9.78 (38-75) years.
Regarding age and sex, there were no significant differences between the groups (p > 0.05). The mean postoperative 1st day, 1st week, 1st month, 3rd month, 6th month, and 12th month IOPs were significantly lower than the mean preoperative IOP in both groups (p < 0.05). The mean number of anti-glaucomatous agents used postoperatively was significantly lower than the mean preoperative number for both groups (p < 0.05). There was a significantly smaller need for needling in the transconjunctival group (p < 0.05).
Xen implantation is a safe and effective method of reducing IOP and anti-glaucomatous dependence. Potential postoperative complications can be resolved easily. There were no significant differences between the standard method and the transconjunctival method in respect of IOP and re-use of anti-glaucomatous agents. However, there was a significantly smaller need for needling in the transconjunctival group. We recommend further studies to investigate long-term results.
比较经结膜(transconjunctival,ab-externo)和标准(ab-interno)两种不同的 Xen 植入技术。
43 例原发性开角型青光眼(POAG)患者行经结膜(transconjunctival,ab-externo)技术 Xen 植入术,其中男性 20 例(46.5%),女性 23 例(53.5%)。年龄 41-74 岁,平均 61.76±8.81 岁。44 例 POAG 患者行标准(ab-interno)技术 Xen 植入术,其中男性 21 例(47.7%),女性 23 例(52.3%)。年龄 38-75 岁,平均 63.80±9.78 岁。
两组患者年龄、性别比较差异无统计学意义(p>0.05)。两组术后第 1、1 周、1 个月、3 个月、6 个月、12 个月眼压均明显低于术前(p<0.05)。两组术后降眼压药物使用量均明显少于术前(p<0.05)。结膜下组需要针刺的次数明显减少(p<0.05)。
Xen 植入术是一种安全有效的降低眼压和减少抗青光眼药物依赖的方法。术后潜在并发症容易解决。标准法与经结膜法在眼压和抗青光眼药物的再利用方面无显著差异。但结膜下组需要针刺的次数明显减少。我们建议进一步研究以探讨长期结果。